Arvaya Healthcare Ltd
Incorporated in 1985, Bijoy Hans Ltd offers medical and lifestyle solutions through physical infrastructure and digital platforms.[1]
- Market Cap ₹ 560 Cr.
- Current Price ₹ 117
- High / Low ₹ 145 / 25.4
- Stock P/E 4.18
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 30.6%
- Earnings include an other income of Rs.140 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 911 | |
| 839 | |
| Operating Profit | 72 |
| OPM % | 8% |
| 140 | |
| Interest | 41 |
| Depreciation | 62 |
| Profit before tax | 109 |
| Tax % | 17% |
| 90 | |
| EPS in Rs | 14.63 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 78% |
| 1 Year: | 383% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| -3 | |
| -7 | |
| 8 | |
| Net Cash Flow | -2 |
| Free Cash Flow | -8 |
| CFO/OP | -5% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses (Headcount Proxy) Rupees ・Standalone data |
|
|||||||||
| Interest Income on Deposits Rupees ・Standalone data |
||||||||||
| Non-Current Investments (Investment Portfolio) Rupees ・Standalone data |
||||||||||
| Purchases of Stock-in-Trade Rupees ・Standalone data |
||||||||||
| Revenue Mix: Revenue from Operations as % of Total Revenue % ・Standalone data |
||||||||||
| Stock-in-Trade (Trading Inventory) Rupees ・Standalone data |
||||||||||
| Term Deposits with Banks Rupees ・Standalone data |
||||||||||
| Trade Receivables Rupees ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Board Meeting To Be Held On 26Th August 2026
- Board meets 26 Aug 2026 to consider RPT slump-sale acquisition of Navahmedi Solution's undertaking using rights issue proceeds.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Intimation for the shifting of Registered office of the Company from State of Assam to State of Maharashtra in Form INC-26
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- Postal ballot passed 6 resolutions on 13 Aug 2026, including Sushodha acquisition and preferential issue.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Pursuant to the meeting of Board held on 12th August 2026, the unaudited Financial Results for the 1st Quarter ended 30th June 2026 published in …
-
Announcement Under Regulation 30 Of LODR
- Board approved incorporation of wholly owned subsidiary in India for insurance broking services, subject to IRDA approval.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1]
BHL is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics, and investments.